TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00290888

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acromioplasty

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acromioplasty
Study: NCT00677612

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGFR1 and VEGFR2
Description: Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with Tegafur/Uracil/Folinate chemotherapy.
Study: NCT02407821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Dose will be initiated at 5 mg daily. At two weeks, a safety and tolerability assessment will be performed, and if tolerated, the dose will be increased to 10 mg daily. At 24 weeks, the medication will be titrated downwards to 5 mg daily for a further two weeks before discontinuation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The matching placebo will be up-titrated and down-titrated at the same time intervals as the active medication.
Study: NCT04563923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avdoralimab (IPH5401)
Description: Preparation of avdoralimab and preparation of the syringes are to be performed aseptically by site pharmacy qualified personnel.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Superpotent topical steroids are the gold standard treatment for BP. All patients will receive 0.05% Clobetasol propionate cream as follows:~* Patients of less than 45kg of body weight: 2 tubes of 10g/d~* Patients of 45kg and above of body weight: 3 tubes of 10g/d Topical steroids will be applied every day until 15 days after the healing of the last bullous lesion
Study: NCT00435292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: nonsteroidal anti-inflammatory drug

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flavocoxid 250 mg
Description: flavonoid mixture

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: flavocoxid 500 mg
Description: flavonoid mixture
Study: NCT02316808

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant stanol ester
Description: Smoothie that contains plant stanol ester
Study: NCT03359785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luvadaxistat
Description: TAK-831 Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luvadaxistat
Description: TAK-831 Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Matching Placebo Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Matching Placebo Tablets.
Study: NCT03021512

Intervention type: PROCEDURE
Intervention: Phaco with Panoptix
Description: Phacoemulsification with bilateral trifocal intraocular lenses implantation
Study: NCT03209700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC-AFP
Description: Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cells.
Study: NCT02316808

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Smoothie that contains placebo
Study: NCT03156543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jumpstart Dressing
Description: JumpStart™ is a wireless, advanced microcurrent generating, dressing used for the management of surgical incision sites. Microcell batteries made of silver and zinc, generate an electrical current when activated by conductive fluids, such as saline, hydrogel or wound exudate. These microcells create low voltage electrical fields to stimulate the surrounding area and to provide antimicrobial protection to assist with wound healing. JumpStart has demonstrated superior broad spectrum bactericidal activity of a wound dressing against antibiotic-resistant strains of wound isolates within 24 hours.~It will be applied pre-op in all patients and post operatively in group B
Study: NCT03828799

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Folfirinox + regorafenib
Description: folfirinox : from day 1 to day 3 regorafenib : day 4 to day 10 a cycle during 14 days
Study: NCT02876107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT03359785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Matching Placebo Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Matching Placebo Tablets.
Study: NCT00724854

Intervention type: BIOLOGICAL
Intervention: PegIntron (peginterferon alfa-2b; SCH 54031)
Description: PegIntron administered in accordance with approved labeling

Intervention type: BIOLOGICAL
Intervention: PegIntron (peginterferon alfa-2b; SCH 54031)
Description: PegIntron administered in accordance with approved labeling

Intervention type: DRUG
Intervention: Rebetol (ribavirin; SCH 18908)
Description: Rebetol administered in accordance with approved labeling

Intervention type: DRUG
Intervention: Rebetol (ribavirin; SCH 18908)
Description: Rebetol administered in accordance with approved labeling
Study: NCT04552639

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Newbridge Eating disorders Activity Treatment group
Description: A compulsive exercise cognitive-behavioural based group, for children and adolescents diagnosed with an eating disorder. It was devised for eating disorders including Anorexia Nervosa, Bulimia Nervosa and Other Specified Feeding or Eating Disorder. This treatment is semi-structured and problem-oriented, which focuses on tackling the factors and processes that maintain compulsive exercise behaviour.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Newbridge House treatment as usual
Description: Multi-disciplinary eating disorder treatment (including; psychiatry, individual therapy, group therapy, dietetic support, occupation therapy and nursing excluding NEAT group).
Study: NCT02224287

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Technologist control of fluoroscopy
Description: Technologist control of fluoroscopy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgeon control of fluoroscopy
Description: Surgeon control of fluoroscopy
Study: NCT04314999

Intervention type: DIAGNOSTIC_TEST
Intervention: Examination of stool samples
Description: Tests for diagnosis of parasitic diseases
Study: NCT04234529

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AMATEA™
Description: AMATEA™ is a patented dietary supplement consisting of a unique blend of caffeine and polyphenol antioxidants; standardized at 20% caffeine, 30% chlorogenic acids (similar to green coffee).~Total of 1.35g of AMATEA containing 270mg of caffeine.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: 1.08g of microcellulose and 270mg of caffeine.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1.35g of microcellulose
Study: NCT02974959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gammaCore active device
Description: The nVNS therapy will be performed using the gammaCore-R (electroCore LLC, NJ), which is an external hand-held vagal nerve stimulator. The gammaCore-R produces a low voltage electric signal consisting of five 5000 Hz pulses that are repeated at a rate of 25 Hz. It allows for a 120 second stimulation session. The stimulation will occur twice daily, one time in the morning and one time in the evening. This should be done as close to 12 hours apart as possible and should occur twice daily for the entire 12 week study period.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: gammaCore sham device
Description: The sham device appears identical to the gammaCore but does not provide a frequency of stimulation powerful enough to stimulate either efferent or afferent fibers of the vagus nerve. However, it does supply a low frequency current which will cause a tingling of this skin to improve blinding of the patients.
Study: NCT02135328

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Radio Story
Description: For the purposes of this study a Radio Story is an audio recorded story of about a family's success story about type 2 diabetes mellitus prevention and management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audio brochure
Description: The control participants listened to an adio version of a standard brochure about prevention and management of type 2 diabetes.
Study: NCT04360239

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Fish-oil formulation of two capsules twice daily (3000 mg of EPA and DHA).
Study: NCT00709293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Thymocyte Globulin
Description: Thymoglobulin (1.5 mg/kg body weight) will be infused through a peripheral intravenous line over a minimum of 6 hours. The infusion will be started at the time of donor visualization (once it is confirmed the transplant is proceeding). The peri-operative nurse or anesthesiologist will be responsible for drug infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline will be utilized as a placebo comparator. It will be infused in the same fashion as the Thymoglobulin in the intervention arm.
Study: NCT01378702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mistletoe preparations
Description: 1 ampoule (1ml) twice per week subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mistletoe preparations
Description: 1 ampoule (1ml) twice per week subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mistletoe preparations
Description: 1 ampoule (1ml) twice per week subcutaneously
Study: NCT03215303

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: In the first moment, CPAP will be installed, and the researcher will hold a mask in the position in which it is coherent, explaining the method to the patient and allowing their gradual adaptation. Patients will adapt for a few minutes to make sure the mask is consistent with the specifications, so that the patient is comfortable. Participants in the intervention group will start with a PEEP of 1cmH2O that will increase by 2 cmH2O until a PEEP of 10 cmH2O is reached. Therefore, participants in the intervention group will remain with CPAP, PEEP of 10cmH2O, FiO2 0.21, for a period of 40 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: In the first moment, CPAP will be installed, and the researcher will hold a mask in the position in which it is coherent, explaining the method to the patient and allowing their gradual adaptation. Patients will adapt for a few minutes to make sure the mask is consistent with the specifications, so that the patient is comfortable. Participants in the intervention group will start with a PEEP of 1cmH2O that will increase by 2 cmH2O until a PEEP of 10 cmH2O is reached. Therefore, participants in the intervention group will remain with CPAP, PEEP of 10cmH2O, FiO2 0.21, for a period of 40 minutes.
Study: NCT02918461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emerging from the Haze class
Description: A 6-week class designed to combat chemotherapy-induced cognitive dysfunction. Patients will report symptoms at 6 months and 1 year after the end of their Haze class.
Study: NCT02035436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-sedation
Description: Patients are awake or have natural sleep during mechanical ventilation. Pain is treated with morphine iv.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control: Sedation
Description: Continuous iv-sedation (propofol first 48 hours, from then midazolam) to Ramsey 3-4 with a daily wake up attempt, where sedation is stopped until patient is awake.
Study: NCT03172962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Specific strength training exercises for the lumbar and abdominal muscles for 8 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care (control)
Description: Will receive the usual care at the hospital

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care (control)
Description: Will receive the usual care at the hospital
Study: NCT02010333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ha44 Gel 0.74% w/w
Description: HA44 Gel 0.74% comprises of Abametapir as the active pharmaceutical ingredient and Benzyl Alcohol as one of the excipients.
Study: NCT03479294

Intervention type: DRUG
Intervention: Shenlingcao Oral Liquid
Description: Shenlingcao Oral Liquid is a health product, and its main components are American ginseng, lucidum, Cordyceps fermented powder Cs-4, rose, maltitol and water. Shenlingcao Oral Liquid can relieve physical fatigue and enhance immunity.
Study: NCT04956315

Intervention type: DIAGNOSTIC_TEST
Intervention: Side-to-side difference (reproducibility)
Description: The experienced examiner performed tests on 20 healthy subjects

Intervention type: DIAGNOSTIC_TEST
Intervention: Side-to-side difference (availability)
Description: Two examiners performed the test on one healthy subject with both devices for ten consecutive days.

Intervention type: DIAGNOSTIC_TEST
Intervention: Side-to-side difference (Accuracy)
Description: 200 ACL rupture and 200 healthy subjects were recruited as contrast to compare the accuracy of the devices in diagnosing ACL rupture.
Study: NCT01493102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: Vasopressin will be reduced first (0.01 U/hour)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Norepinephrine will be reduced first (0.1 microgram/kg/hour)
Study: NCT02338895

Intervention type: DEVICE
Intervention: Ultrasound
Description: Ultrasound of inferior vena cava and kidneys
Study: NCT00404755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: Escitalopram: wk 1: 10 mg/d; wks 2-3: 20 mg/d; wk4: 30 mg/d; wks 5-6: 40 mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion
Description: bupropion XL 150 mg/d increasing as tolerated and not remitted by 150 mg/d to maximal dose of 450 mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imipramine
Description: imipramine 50 mg/d increasing twice weekly by 50 mg/increase to 200 mg/d, then 50 mg increase/week to 300 mg/d; all dose increases if tolerated and not remitted
Study: NCT02174029

Intervention type: PROCEDURE
Intervention: Ventilation- mandatory
Description: Patient days during which only a mandatory ventilation mode was used and prior to this no voluntary mode was used.

Intervention type: PROCEDURE
Intervention: Ventilation- voluntary mode only
Description: Patient days on a voluntary mode with no preceding days with a majority of time spend on a mandatory mode

Intervention type: PROCEDURE
Intervention: Voluntary with preceding mandatory
Description: Patient days on a voluntary vent mode with at least one day prior during which the majority of the vent mode was mandatory.
Study: NCT02523157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wellbeing Plan
Description: The Wellbeing Plan is a short self-help leaflet designed to improve emotional wellbeing of women during and after pregnancy by providing information, raising awareness, helping a woman identify her own symptoms, provide coping strategies, and identify key people who can support the woman during this time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control task
Description: Information about physical health in pregnancy, matched for readability (Flesch score) and length/duration with the Wellbeing Plan
Study: NCT03629340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg PO BID x 1 week then increase to 1000 mg PO BID x 11 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) BID (two times each day) for 12 weeks
Study: NCT02613468

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: collection of periodontal records
Description: 1. Clinic attachment level~2. Probing depth~3. Gingival index~4. Plaque index~5. Bleeding on probing were performed in all groups. These measurements were performed at the end of each trimester.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: collection of periodontal records
Description: 1. Clinic attachment level~2. Probing depth~3. Gingival index~4. Plaque index~5. Bleeding on probing were performed in all groups. These measurements were performed at the end of each trimester.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: collection of periodontal records
Description: 1. Clinic attachment level~2. Probing depth~3. Gingival index~4. Plaque index~5. Bleeding on probing were performed in all groups. These measurements were performed at the end of each trimester.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pregnancy parameters
Description: Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit and birth weight were evaluated.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pregnancy parameters
Description: Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit and birth weight were evaluated.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pregnancy parameters
Description: Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit and birth weight were evaluated.
Study: NCT03155100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib for Inj 60 milligram (MG)
Description: All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab 400 MG
Description: All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
Study: NCT02613468

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Initial Periodontal Therapy
Description: Initial Periodontal Therapy is completed ( Supragingival and subgingival calculus elimination, root planning, polishing etc.) This treatment is considered to be the safest time for pregnant mothers was performed in 2 trimester.
Study: NCT02876107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV
Study: NCT00252694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: candesartan
Description: 32 mg oral tablet
Study: NCT03156543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jumpstart Dressing
Description: JumpStart™ is a wireless, advanced microcurrent generating, dressing used for the management of surgical incision sites. Microcell batteries made of silver and zinc, generate an electrical current when activated by conductive fluids, such as saline, hydrogel or wound exudate. These microcells create low voltage electrical fields to stimulate the surrounding area and to provide antimicrobial protection to assist with wound healing. JumpStart has demonstrated superior broad spectrum bactericidal activity of a wound dressing against antibiotic-resistant strains of wound isolates within 24 hours.~It will be applied pre-op in all patients and post operatively in group B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Dressing
Description: This is a standard of care bandage that will be placed on participants in group A post operatively
Study: NCT01995240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: 0.1 ml/kg Gadovist is administered at 5 ml/s followed by a 15 ml saline flush

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: 0.1 ml/kg Gadovist is administered at 5 ml/s followed by a 15 ml saline flush
Study: NCT01499368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lafutidine
Description: Lafutidine 20mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Description: Famotidine 40mg/day

Intervention type: DRUG
Group type: OTHER
Intervention: Omeprazole
Description: Omeprazole 20mg/day
Study: NCT04742452

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superior Capusular Reconstruction
Description: Superior capsular reconstruction is one treatment option for massive and irreparable rotator cuff tears. The superior shoulder capsule, a thin membranous structure located on the inferior surface of the supraspinatus and infraspinatus muscles, is often torn in this type of rotator cuff tear. In superior capsular reconstruction, this structure is reconstructed with acellular dermal allograft.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Partial Rotator Cuff Repair
Description: Partial rotator cuff repair can be performed, in conjunction with other procedures such as subacromial decompression and biceps tenodesis, when a rotator cuff tear is not amenable to a complete repair.
Study: NCT04268199

Intervention type: DRUG
Group type: OTHER
Intervention: Bortezomib Injection
Description: Subcutaneous injection
Study: NCT02710565

Intervention type: OTHER
Group type: OTHER
Intervention: Cohort
Description: Obtaining additional EBUS TBNA samples for cell culture
Study: NCT02206568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: URAL